3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Renal Cell
64
Neoplasm Metastasis
25
Kidney Neoplasms
21
Neoplasms
16
Breast Neoplasms
15
Carcinoma, Non-Small-Cell Lung
13
Urinary Bladder Neoplasms
12
Prostatic Neoplasms
10
Lung Neoplasms
8
Brain Neoplasms
8
Melanoma
7
Colorectal Neoplasms
7
Pancreatic Neoplasms
6
Ovarian Neoplasms
6
Neuroendocrine Tumors
6
Liver Neoplasms
6
Glioblastoma
6
Gastrointestinal Stromal Tumors
6
Carcinoma, Hepatocellular
6
Thyroid Neoplasms
5
Thymoma
5
Small Cell Lung Carcinoma
5
Recurrence
5
Multiple Myeloma
5
Esophageal Neoplasms
5
Carcinoma
5
Uveal Melanoma
4
Stomach Neoplasms
4
Sarcoma
4
Adenocarcinoma
4
Interventions
Pentoxifylline
3
Tocopherols
2
tremelimumab
1
ruxolitinib
1
maltodextrin
1
durvalumab
1
atezolizumab
1
Vitamin E
1
Sunitinib
1
Standard of Care
1
Specimen Handling
1
Simvastatin
1
Pravastatin
1
Physical Therapy Modalities
1
Pharmaceutical Preparations
1
Magnetic Resonance Spectroscopy
1
Losartan
1
Liver Transplantation
1
Ketoprofen
1
Hyperbaric Oxygenation
1
Bevacizumab
1
Amino Acids
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Fibrosis
×
Sunitinib
×
Clear all
NCT01215565
2014-03-13
Fibrolam
Assistance Publique - Hôpitaux de Paris
Phase 2
Terminated
4 enrolled